Second, the most frequent IDH mutations in glioma and AML (IDH1R132H and IDH2R140Q, respectively) are weak D-2-HG producers as compared to the most common point mutation in chondrosarcoma (IDH1R132C) [7]. This evidence concerns the gene IDH1 and central nervous system cancer.